DSIP
A naturally occurring neuropeptide first linked to sleep in animals decades ago. Despite its name, human evidence for a reliable sleep effect is limited and inconsistent, and it remains a research compound.
Quick take
- What it is: a naturally occurring neuropeptide named for its early association with delta-wave (deep) sleep in animal experiments.
- What people use it for: mostly sleep, and informally for stress and recovery.
- What we actually know: despite its name, human evidence for a consistent sleep effect is weak, and findings have been mixed.
- Status: a research compound; not approved by the FDA or other major regulators for any use.
What it is
DSIP, or Delta Sleep-Inducing Peptide, is a naturally occurring neuropeptide first isolated in animal experiments in the 1970s, where it was associated with delta-wave (deep) sleep. The name reflects that early observation rather than a well-established human sleep effect.1
It remains a research compound with no approved medical use, and its biology in humans is still not well understood.
How it works
The precise mechanism of DSIP is not well defined. It has been proposed to influence sleep regulation, the stress (hypothalamic–pituitary–adrenal) axis and some neuroendocrine pathways, but a clear, agreed mechanism has not emerged from the literature.1,2 This uncertainty is itself an important part of understanding the peptide.
What the evidence shows
Animal studies
Early animal work linked DSIP to delta-wave sleep and to effects on stress responses, which is the origin of its name and reputation.2
Human studies
Human studies have been limited and inconsistent. Some early reports suggested effects on sleep or stress markers, but results have not been reliably reproduced, and there is no robust body of controlled human trials establishing a dependable sleep benefit.3 This gap between the evocative name and the weak human evidence is the key point to understand.
Dosages reported in the literature
Informational only. The figures below describe doses reported in research and informal use. They are not a recommendation or a prescription. There is no approved dosing, and any use should be discussed with a qualified healthcare professional.
| Setting | Route | Reported range |
|---|---|---|
| Research / informal use | Subcutaneous / IV | Variable microgram-range protocols; not standardised |
| Approved medical use | — | None — no approved formulation |
Because there are no robust dose-finding human trials, no range here should be read as established as safe or effective.
Safety & side effects
There is limited controlled human safety data for DSIP. Reported informal use does not point to a well-characterised set of common side effects, but this reflects the lack of rigorous study rather than proven safety.3
As with any peptide sold outside a regulated supply chain, product purity and dose accuracy vary between sources, which is an added concern.
Legal & regulatory status
DSIP is not approved by the FDA or other major regulators for any use. It is treated as a research compound, and its legal status for sale and use varies by country and changes over time.1
References
- Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. Journal of Neurochemistry. 2006;97(2):303-309. [PMID 16539679, doi:10.1111/j.1471-4159.2006.03693.x]
- Schoenenberger GA, Monnier M. Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proceedings of the National Academy of Sciences USA. 1977;74(3):1282-1286. [PMID 265572, doi:10.1073/pnas.74.3.1282]
- Bes F, Hofman W, Schuur J, Van Boxtel C. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. Neuropsychobiology. 1992;26(4):193-197. [PMID 1299794]